Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Depreciation (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Accumulated Depreciation for 2 consecutive years, with $14.4 million as the latest value for Q4 2021.

  • On a quarterly basis, Accumulated Depreciation rose 36.44% to $14.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $14.4 million, a 36.44% increase, with the full-year FY2021 number at $14.4 million, up 36.44% from a year prior.
  • Accumulated Depreciation was $14.4 million for Q4 2021 at Relay Therapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $14.4 million in Q4 2021 to a low of $10.5 million in Q4 2020.